Share on StockTwits

A number of firms have modified their ratings and price targets on shares of Intersect ENT (NASDAQ: XENT) recently:

  • Intersect ENT is now covered by analysts at JPMorgan Chase & Co.. They set an “overweight” rating and a $22.00 price target on the stock.
  • Intersect ENT is now covered by analysts at Piper Jaffray. They set an “overweight” rating and a $20.00 price target on the stock.
  • Intersect ENT is now covered by analysts at Wedbush. They set an “outperform” rating and a $18.00 price target on the stock.
  • Intersect ENT is now covered by analysts at Leerink Swann. They set an “outperform” rating and a $20.00 price target on the stock.

Shares of Intersect ENT Inc (NASDAQ:XENT) opened at 15.99 on Wednesday. Intersect ENT Inc has a one year low of $12.02 and a one year high of $16.78. The stock has a 50-day moving average of $13.53 and a 200-day moving average of $13.53. The company’s market cap is $359.8 million.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.